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Shared Genetic Predisposition in Peripartum and Dilated 
Cardiomyopathies
To the Editor: Ware et al. (Jan. 21 issue)1 de-
scribe a very similar distribution of presumably 
causative genetic variants in TTN and other genes 
in women with peripartum cardiomyopathy and 
in persons with idiopathic dilated cardiomyopa-
thy. The clinical outcome of peripartum cardio-
myopathy is highly variable, ranging from full 
recovery to rapid progression to end-stage heart 
failure,2 and the appropriate duration of therapy 
is controversial. I therefore wonder whether analy-
sis of the data of Ware et al. can shed light on 
whether TTN-truncating variants are associated 
with late recovery or persistent left ventricular 
dysfunction in patients with peripartum cardio-
myopathy.
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To the Editor: Ware et al. report a striking sim-
ilarity of the presumed genetic causes of peripar-
tum and idiopathic dilated cardiomyopathies in a 
large series of women. In our recent analysis of 
data from a large administrative U.S. database 
(the Healthcare Cost and Utilization Project Na-
tional Inpatient Sample), we found remarkable 
similarity between patients with dilated cardio-
myopathy and those with peripartum cardiomy-
opathy in terms of demographic and clinical 
characteristics and patient outcomes in pregnancy 
during the hospitalization for delivery.1 Approxi-
mately 30% of the women in each cohort were 
black, and the two cohorts had similarly elevated 
rates of death, heart failure, arrhythmias, and pre-
eclampsia spectrum disorders. Perhaps some of 
the patients (mis)classified as having peripartum 
cardiomyopathy were women with an asymptom-
atic dilated cardiomyopathy before pregnancy, and 
the hemodynamic demands of pregnancy wors-
ened the degree of left ventricular dysfunction, 
leading to clinical heart failure. Have the authors 
considered whether the overlap in the reported 
genetic variants is consequent to the same dis-
ease presenting differently owing to pregnancy?
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The authors reply: In response to Biteker: we 
agree that there is an important need for prog-
nostic indicators for women with peripartum 
cardiomyopathy. Our study was not powered to 
test whether genetic variants correlate with clini-
cal outcomes, nor did we have information on 
clinical outcomes for all patients. We did, how-
ever, have information for 1 year after enrollment 
on the 83 women in the Investigations in Preg-
nancy Associated Cardiomyopathy (IPAC) study. 
We noted that women enrolled in that study who 
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bore truncating variants in TTN had a signifi-
cantly lower average left ventricular ejection frac-
tion 1 year after enrollment than did the women 
with no truncating variants (mean [±SD], 44±17% 
vs. 54±8%; P = 0.005). The burden was largely seen 
in women of African descent. The results thus 
suggest that the presence of a truncating variant 
in TTN may presage persistent left ventricular dys-
function. However, these post hoc results must 
be interpreted with caution, and larger prospec-
tive studies are needed.
In response to Stergiopoulos et al.: we agree 
that peripartum and idiopathic dilated cardio-
myopathies share many characteristics, including 
a high burden of truncating variants in TTN. We 
do not have data to directly address the question 
of whether women classified as having peripar-
tum cardiomyopathy had cardiomyopathy before 
pregnancy. However, dilated cardiomyopathy typ-
ically manifests decades later than peripartum 
cardiomyopathy. In addition, in our study, women 
with TTN variants and those without such vari-
ants had similar numbers of previous pregnan-
cies without development of the disease (mean, 
2.9±2.3 and 2.8±1.9 pregnancies, respectively; 
P = 0.84). Together, these observations do not sup-
port pregnancy-induced clinical expression of a 
preexisting condition, though we cannot rule out 
this possibility. With respect to the question of 
whether peripartum and idiopathic dilated car-
diomyopathies are the same disease presenting 
differently owing to pregnancy, we agree that 
this appears likely, at least for a subset of each 
disease. In that context, we note that nearly all 
TTN variants in the IPAC cohort occurred in 
women without a hypertensive disorder, despite 
the 46% prevalence of hypertension in the cohort. 
Peripartum cardiomyopathy may thus have two 
different causes — genetic variation in genes 
associated with dilated cardiomyopathy such as 
TTN and preeclampsia. As noted above, these 
post hoc results must be interpreted with caution, 
and larger prospective studies are needed.
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Weekly vs. Every-3-Week Paclitaxel for Ovarian Cancer
To the Editor: Chan et al. (Feb. 25 issue)1 found 
a marginal benefit of dose-dense (weekly) chemo-
therapy over standard chemotherapy in a group 
of 112 women with ovarian cancer who did not 
receive bevacizumab, a subgroup that represents 
a mere 16% of the whole. The use of progression-
free survival, instead of overall survival, in trials 
of ovarian-cancer therapies will exaggerate the 
benefit of a therapy that delays progression but 
has no effect on survival. The degree of exaggera-
tion is greatest for trials, such as this one, in 
which the overall survival is poor, because the 
worse the survival is, the farther the hazard ratio 
associated with the intervention will fall below 
unity. In the present study, the 4-year survival 
rate was 44%; the high mortality can be attrib-
uted to the low rate of acceptance of neoadjuvant 
chemotherapy (13%) and the far lower rate of 
microscopic residual disease than gross residual 
disease (24% vs. 63%) after surgery. These two 
treatment factors are of far greater importance 
than is any minor modification to the chemo-
therapy regimen,2 and improving these should be 
our goal.
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To the Editor: Chan et al. report that weekly 
paclitaxel and carboplatin, as compared with 
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